Document is current
Any future updates will be listed below
-
Authors
Daudén, Esteban https://orcid.org/0000-0002-0676-1260
Belinchón, Isabel https://orcid.org/0000-0002-6007-7320
Colominas-González, Elena https://orcid.org/0000-0002-6835-2868
Coto, Pablo
de la Cueva, Pablo https://orcid.org/0000-0003-4807-3551
Gallardo, Fernando https://orcid.org/0000-0002-8996-3828
Poveda, Jose Luis https://orcid.org/0000-0003-1800-6198
Ramírez, Esther https://orcid.org/0000-0003-3053-7426
Ros, Sandra https://orcid.org/0000-0002-6267-1059
Ruíz-Villaverde, Ricardo https://orcid.org/0000-0002-0381-6174
Cabezas, Isabel https://orcid.org/0009-0008-8726-9913
Lizán, Luis https://orcid.org/0000-0001-6039-2454
-
Funding
Funding for this research was provided by:
Almirall
- License Information
-
More Information
Article History
Received: 18 June 2025
Accepted: 9 July 2025
First Online: 18 July 2025
Declarations
:
: Esteban Daudén has served as advisory board member and consultant, and reports grants, research support, participation in clinical trials and honorarium for speaking, for AbbVie, Abbott, Almirall, Amgen-Celgene, Johnson & Johnson/Janssen-Cilag, Leo-Pharma, Novartis, Pfizer, MSD-Schering-Plough, Lilly, UCB, Bristol-Myers and Boehringer-Ingelheim. Isabel Belinchón has received fees as a consultant and/or speaker and has participated in clinical trials sponsored by the following pharmaceutical companies whose therapeutic arsenal includes drugs used to treat psoriasis: Janssen Pharmaceuticals Inc, Almirall, Lilly, AbbVie, Novartis, Celgene, Biogen, Amgen, Leo-Pharma, Pfizer-Wyeth, BMS, UCB, and MSD-Schering-Plough. Pablo Coto has served as speaker and consultant, and has participated in educational and scientific projects or clinical trials for AbbVie, Amgen, Almirall, Incyte, Leo-Pharma, UCB, and Sanofi. Pablo de la Cueva has served as a consultant, speaker and investigator for AbbVie, Almirall, BMS, Boehringer-Ingelheim, Celgene, Johnson & Johnson, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, and UCB. Isabel Cabezas and Luis Lizán work for an independent research entity (Outcomes’10) that received funding from Almirall to coordinate and conduct the project. Elena Colominas-González, Fernando Gallardo, Jose Luis Poveda, Esther Ramírez, Sandra Ros, and Ricardo Ruíz-Villaverde have nothing to disclose.
: Ethical approval for this study was obtained from the Clinical Research Ethics Committee (CREC) of Hospital La Princesa (Madrid) (Reference number: LIB 14/2007) and complied with the Helsinki Declaration of 1975, as revised in 1983. All patients and HCP’s provided informed consent for this study.
